Bionomics (NASDAQ:BNOX) Downgraded by HC Wainwright to Neutral
Bionomics (NASDAQ:BNOX) Downgraded by HC Wainwright to Neutral
HC Wainwright downgraded shares of Bionomics (NASDAQ:BNOX – Get Rating) from a buy rating to a neutral rating in a report issued on Monday, The Fly reports.
HC Wainwright 下调了的股票评级 Bionomics(纳斯达克股票代码:BNOX — 获取评级) The Fly报道,在周一发布的报告中,从买入评级到中性评级。
Separately, Loop Capital initiated coverage on shares of Bionomics in a research report on Tuesday, November 1st. They issued a buy rating and a $23.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $16.67.
另外,Loop Capital在11月1日星期二的一份研究报告中开始报道Bionomics的股票。他们为该公司发布了买入评级和23.00美元的目标价。两位股票研究分析师对该股进行了持有评级,四位对该股给出了买入评级。根据MarketBeat的数据,该股目前的平均评级为中度买入,共识目标价为16.67美元。
Bionomics Price Performance
生物学价格表现
NASDAQ BNOX opened at $4.71 on Monday. The company has a fifty day simple moving average of $7.51 and a 200 day simple moving average of $7.33. Bionomics has a 12-month low of $4.71 and a 12-month high of $13.76.
纳斯达克BNOX周一开盘价为4.71美元。该公司的五十天简单移动平均线为7.51美元,200天简单移动平均线为7.33美元。Bionomics创下12个月低点4.71美元,12个月高点13.76美元。
Bionomics Company Profile
生物学公司简介
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
Bionomics Limited是一家临床阶段的生物制药公司,发现并开发了用于治疗中枢神经系统疾病和癌症的新型候选药物。该公司的主要候选药物包括 BNC210,这是a7烟碱乙酰胆碱受体的阴性变构调节剂,该药物正在治疗社交焦虑症的2期临床试验和治疗创伤后应激障碍的2b期临床试验中。
See Also
另见
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- 免费获取 StockNews.com 生物学研究报告 (BNOX) 的副本
- 你购买Palantir的决定可能只是时间问题
- 卡特彼勒和迪尔准备在 2023 年反弹吗?
- 随着 I-GO 抵达欧洲,Mullen Automotive 大吃一惊
- 2023 年,太阳会照在这三只大盘太阳能股票上吗?
- Lucid Motors 面临的现实可能会给看涨的看法蒙上阴影
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
接收《生物经济学日报》的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Bionomics及相关公司的最新新闻和分析师评级的简要每日摘要。